Understanding the Category Before Stocking It
The term "skin booster" is used broadly across the aesthetic market. In clinical and commercial conversations it can refer to several distinct product types, including low-viscosity hyaluronic acid preparations, high-concentration bio-remodelling formulations, polynucleotide agents, and mesotherapy cocktails. For a practitioner making stocking decisions, conflating these categories is a practical problem. Each has a different mechanism, a different evidence base, different handling requirements and a different patient indication profile.
This guide addresses each category in turn, then outlines a practical framework for building a focused and defensible stocking range. It does not cover injection technique; practitioners should complete formal, hands-on training with any product before clinical use.
Skin Booster Injectables Versus Structural Fillers: The Distinction That Matters
To understand skin booster injectables, it is useful to start with what they are not. Structural dermal fillers, most commonly cross-linked hyaluronic acid gels, are designed to resist degradation and maintain their shape within tissue. They add volume, lift tissue, or efface lines by occupying physical space. Their rheological properties, including G prime (elastic modulus) and viscosity, are calibrated to this purpose. Higher G prime products provide lift; lower G prime products are used in more superficial planes.
Skin boosters operate at a different level of ambition. The treatment intent is qualitative improvement of the skin itself: hydration, texture, elasticity, luminosity, and fine line reduction. They do not provide volumetric augmentation. Most are injected intradermally or into the superficial dermis using a nappage or microdroplet technique, and they are expected to be metabolised and replaced. The treatment protocol typically involves an initial course of sessions followed by maintenance, rather than the single-treatment approach of a volumising filler.
The two categories are not competitive; they are complementary within a thoughtful treatment plan. A structural filler can restore lost volume; a skin booster programme can address the quality of the overlying skin. Practitioners who stock both are better positioned to address the full range of patient concerns, and to avoid the clinical compromise of trying to use a structural filler for a skin quality indication, or vice versa.
The HA Bio-Remodelling Category
Within the broader skin booster classification, the bio-remodelling sub-category has attracted significant clinical attention. Products in this category, of which Profhilo (IBSA Farmaceutici) is the most established in the UK market, are characterised by an exceptionally high hyaluronic acid concentration in a minimally cross-linked or thermally stabilised form. The hypothesis underlying their mechanism is that this formulation profile allows the HA to spread through tissue planes and interact with cell surface receptors, stimulating the production of collagen types I, III and IV, elastin and adipocyte progenitor cells.
Profhilo has been the subject of published clinical studies, including a double-blind randomised controlled trial published in the Journal of Cosmetic Dermatology, which demonstrated statistically significant improvements in skin laxity and elasticity compared to placebo. Practitioners evaluating any HA bio-remodelling product should look for similarly rigorous clinical data rather than relying on category association or brand marketing.
From a procurement perspective, HA bio-remodelling products are typically supplied as pre-filled syringes with a specified storage temperature range stated in the product SPC. Cold chain integrity during delivery is important; practitioners should verify this with their supplier. These products tend to have a premium price point reflecting the technology involved in their manufacture, and stocking decisions should account for realistic treatment frequency in the practice population.
The Polynucleotide Category
Polynucleotides (PN), also referred to as polydeoxyribonucleotides (PDRN), represent a distinct and growing segment of the aesthetic injectable market. They are derived from highly purified salmon or trout sperm DNA through a controlled extraction and purification process that eliminates immunogenic proteins. The primary mechanisms attributed to polynucleotides in peer-reviewed literature include stimulation of the A2A adenosine receptor pathway, which supports tissue regeneration and has anti-inflammatory effects, alongside a direct structural role in providing a scaffold for tissue repair.
Clinical studies, including publications in the Journal of Drugs in Dermatology and the Aesthetic Surgery Journal, have examined polynucleotides for applications including skin laxity, periorbital rejuvenation and post-procedural recovery support. The evidence base continues to develop, and practitioners should review the primary literature alongside the specific clinical data package provided by each product manufacturer.
The polynucleotide market includes products from several manufacturers, notably Nucleofill (Mastelli), Plinest and Newest (Evolutionary Beauty) and PDRN-based products from a number of European manufacturers. Product concentration, molecular weight distribution and purification standards vary between manufacturers, and these differences are clinically meaningful. When evaluating which product to stock, practitioners should look for peer-reviewed evidence specific to that product or its specific formulation category, not evidence derived from a chemically different preparation.
Polynucleotide injectables require the same storage discipline as HA-based products: adherence to the manufacturer's SPC temperature guidance, cold chain verification on delivery, and batch and expiry records in every patient file.
Mesotherapy Agents: A Conceptual Overview
Mesotherapy is a broad treatment category involving the intradermal or subcutaneous microinjection of low-dose active substances, typically comprising vitamins, minerals, amino acids, hyaluronic acid in low concentrations, or enzyme preparations such as phosphatidylcholine. The category is more heterogeneous than HA bio-remodelling or polynucleotides, and the evidence base for individual formulations varies considerably.
Practitioners considering mesotherapy products should be precise about which product they are evaluating and should look for clinical evidence specific to that formulation. The MHRA regulates injectable aesthetic products as medical devices, and any mesotherapy product without appropriate CE or UKCA marking falls outside the regulatory framework. This is a procurement filter that should be applied before any other consideration.
Building a Focused Stocking Range
A coherent approach to stocking skin booster injectables begins with four questions.
Training held. A practitioner should only stock products they are trained and competent to use. Stocking a product against a future training date creates the risk of use under pressure before competence is established. Training should precede procurement, not follow it.
Patient demand. The practice population determines which categories are worth holding in regular stock. A clinic serving an older demographic with skin laxity concerns may find HA bio-remodelling products generate strong repeat demand. A clinic with a younger patient base focused on preventative skin health may see more appetite for polynucleotide protocols. Stocking decisions based on trend rather than observed patient need tend to produce slow-moving inventory and expiry waste.
Predictable reordering. A stocking range should be sized to allow regular reordering within the product's shelf life. Holding large volumes of a slow-moving product to take advantage of bulk pricing frequently results in expiry loss that erodes the apparent saving. A smaller, faster-turning stock is generally more financially sound and reduces the risk of using product that is approaching its expiry date.
Provenance and documentation. Every product in the range should be sourced from a supplier who can provide clear documentation of regulatory status, cold chain compliance, batch traceability and, where applicable, UK or EU market authorisation. This is not bureaucratic caution; it is the minimum standard required to demonstrate clinical governance in a Care Quality Commission (CQC) regulated environment, and to act effectively in the event of an MHRA safety communication.
A Note on the Aesthetic Practitioner Buying Guide Mindset
The most effective clinic stocking strategies are built around a small number of well-understood products used with consistent technique and supported by thorough patient documentation. A practitioner who knows three products deeply is better placed than one who holds ten products superficially. Range expansion should be incremental, evidence-led and tied to training completion rather than driven by supplier promotion or market trend alone.
When evaluating a new product for the first time, it is reasonable to request the product's clinical dossier from the supplier, to review published peer-reviewed literature independently, and to consult training providers who have experience with the specific formulation. This level of diligence is consistent with the professional standards expected by the Joint Council for Cosmetic Practitioners (JCCP) and the British College of Aesthetic Medicine (BCAM).
Frequently Asked Questions
What is the key difference between a skin booster and a structural dermal filler?
Structural dermal fillers are designed to add volume, define contours or efface folds by physically occupying space within the tissue. Skin boosters, by contrast, aim to improve skin quality, hydration, elasticity and luminosity, primarily at the intradermal level, without creating volume change. The two categories can be complementary within a treatment plan, but they are not interchangeable and should not be positioned as such to patients.
What does 'bio-remodelling' mean in the context of HA-based skin boosters?
Bio-remodelling refers to the hypothesis that certain high-concentration, low-cross-linked hyaluronic acid formulations stimulate the skin's own collagen, elastin and adipocyte progenitor cells rather than simply providing a mechanical filling effect. Products in this category, such as Profhilo (manufactured by IBSA), are supported by published clinical data including randomised controlled studies, though practitioners should review the primary literature directly rather than relying on marketing summaries.
Are polynucleotides the same as skin boosters?
Polynucleotides (PN or PDRN) are a distinct category of injectable aesthetic agent derived from highly purified salmon or trout DNA. They are not hyaluronic acid based and work through different mechanisms, principally tissue repair and regeneration pathways. Some practitioners classify them broadly within the skin booster category because the treatment intent is skin quality improvement rather than volume addition, but the underlying science is different from HA bio-remodelling products.
What should a practitioner consider before adding a new skin booster to their stocking range?
The core questions are: do I have the clinical training to use this product correctly; is there consistent patient demand in my practice population; can I order it reliably from a compliant supplier with verifiable provenance; and can I reorder in quantities that avoid waste? Adding products that require specialist technique without the corresponding training, or stocking slow-moving products that approach expiry, increases clinical and financial risk simultaneously.
What regulatory status do polynucleotide injectables hold in the UK?
Polynucleotide-based aesthetic injectables are generally regulated as medical devices in the UK, subject to the Medical Devices Regulations 2002 (as amended). Practitioners should confirm the regulatory status of any specific product with the supplier and verify that it has appropriate CE or UKCA marking. Products without clear regulatory documentation should not be purchased, regardless of price.